Monday , September 25 2017
Home / Cannabis Based Medicine

Cannabis Based Medicine

Flex Pharma’s FLX-787 Granted FDA Fast Track Status for Treatment of Severe Muscle Cramps Associated with ALS

Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with serious neurological diseases including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Charcot-Marie-Tooth (CMT), today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for …

Read More »

Cannabics Pharmaceuticals Receives Positive Results in Drug Sensitivity Tests on CTCs

TEL AVIV, Israel, June 30, 2017 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) today announced it received positive results from screening necrosis (cell death) of circulating tumor cells, from cancer patients, treated with the cannabinoids CBD and CBDA. These results greatly strengthen the company’s previously accumulated data on cannabinoid anti-tumor activity. …

Read More »

GW Pharma’s Epidiolex Reduces Seizures in Children with Dravet Syndrome

London, UK, May 24, 2017 – GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine …

Read More »

Cannabics Announces Commercialization of Cannabinoids-Based Personalized Diagnostics for Cancer Patients

BETHESDA, Maryland, Feb. 6, 2017 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) today announced it will begin providing personalized cannabinoid anti-tumor tests for cancer patients. The diagnostic tests are based on liquid biopsies of patients suffering from any kind of cancer. The test uses CTC technology that collects cancer cells from patients’ …

Read More »

GW Pharma’s Cannabis-Derived Drug Shows Promise in Brain Cancer Study

London, UK, 7 Feb 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a proprietary combination …

Read More »

Cannabics Announces Specific Ratios of Cannabinoids Led to Apoptosis in MD-MB-231 Breast Cancer Cell Viability

BETHESDA, Maryland, Dec. 1, 2016 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) announced today that results from the company’s Cancer HTS research indicates that specific ratios of Cannabinoids led to Apoptosis in MDA-MB-231 Breast Cancer cell viability. Cannabics Pharmaceuticals is currently developing a personalized treatment based upon screening of patients’ biopsy …

Read More »

Therapix Develops Formulations for a Tablet for Sublingual Administration of THC for Pharmaceutical Use

TEL AVIV, Israel, October 31, 2016 /PRNewswire/ — Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA) the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced the successfully completion of the development phase of a unique formulation of a tablet for sublingual administration for pharmaceutical use. The tablet is …

Read More »

Cannabics Discovers Specific Ratios of THC/CBD Effectuate Reduction in U87MG Glioblastoma Cell Viability

BETHESDA, Maryland, October 20, 2016 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) announced today that results from the company’s latest cancer HTS research overtly conclude that, depending upon the THC/CBD ratio, specific Cannabis extracts are directly contributive to reducing U87MG glioblastoma cell viability. The Company expects that results on additional types …

Read More »

CNF Presents Cannabis in Epilepsy: A Symposium Designed to Bridge the Gap in Communication

MINNEAPOLIS, Oct. 19, 2016 /PRNewswire-USNewswire/ — The Child Neurology Foundation (CNF) is poised to welcome members of the Child Neurology Society (CNS) interested in seeking a deeper understanding of the current science, family experience and advocacy efforts surrounding the use of cannabis for the treatment of epilepsy. The organization will …

Read More »

Medical Genomics Partners with Industry Leaders to Develop Genomics-Based Safety and Quality Standards for Medical Cannabis

WOBURN, Mass.–(BUSINESS WIRE)–Medicinal Genomics (MGC), an innovative molecular information company focused on safety, research, and genetics of therapeutic plants, is partnering with a preliminary group of twelve leading cultivators and processors to develop fully-validated, genomics-based safety and quality standards for medical cannabis. The lack of consistency of strains from the …

Read More »